Effects of HMG-CoA reductase inhibitor on atherosclerosis and multi-lipoprotein profiling in patients without coronary artery disease
Not Applicable
- Conditions
- Patients with hypercholesterolemia
- Registration Number
- JPRN-UMIN000002600
- Lead Sponsor
- agoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have taken statins. 2) Patients who have suffered from acute myocardial infarction for the past 3 months. 3) Patients undergoing CABG or PCI for the past 3 months, or planning CABG or PCIin the study periods. 4) Patients with active malignant tumor. 5) Patients with severe renal dysfunction. 6) Patients with severe hepatic dysfunction. 7) Patients with collagen disease. 8) Patients during pregnancy and nursing. 9) Patients who do not accept informed consent. 10) Patients judged as being inappropriate for this study by investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in endothelial function (PAT), Change in brachial-ankle pulse wave velocity or cardio-ankle vascular index, Change in intima-media thickness (max IMT, mean IMT)
- Secondary Outcome Measures
Name Time Method A percent and amount of changes in following factors 1. Serum lipid profile (TC,LDL-C, HDL-C, TG), apolipoprotein (A1, B), beta-lipoprotein, lipoprotein profile by LipoSEARCH, malondialdehyde-modified LDL, CETP 2. high-sensitive CRP, adiponectin, reactive oxygen metabolites (d-ROMs), fasting inslin